2-chloro-N-(cyclopentylmethyl)-5-(3,5-dioxo-1,2,4-triazin-2-yl)benzamide | 1314188-34-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-N-(cyclopentylmethyl)-5-(3,5-dioxo-1,2,4-triazin-2-yl)benzamide
• CAS: 1314188-34-5
• 化学式: C₁₆H₁₇ClN₄O₃
• 分子量: 348.789
• InChiKey: LADYGXSOCWIHHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  90.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-氨基-2-氯苯甲酸 在 盐酸 、 草酰氯 、 溶剂黄146 、 巯基乙酸 、 sodium hydroxide 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.83h， 生成 2-chloro-N-(cyclopentylmethyl)-5-(3,5-dioxo-1,2,4-triazin-2-yl)benzamide
  参考文献：
  名称：

  Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535

  摘要：

  High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X(7) receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein binding and a predicted short half-life in humans. Multi-parameter optimization was used to address the potency, physicochemical and pharmacokinetic properties which led to potent P2X(7)R antagonists with good disposition properties. Compound 33 (CE-224,535) was advanced to clinical studies for the treatment of rheumatoid arthritis. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.077

文献信息

• Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535
  作者：Allen J. Duplantier、Mark A. Dombroski、Chakrapani Subramanyam、Aimee M. Beaulieu、Shang-Poa Chang、Christopher A. Gabel、Crystal Jordan、Amit S. Kalgutkar、Kenneth G. Kraus、Jeff M. Labasi、Christopher Mussari、David G. Perregaux、Rick Shepard、Timothy J. Taylor、Kristen A. Trevena、Carrie Whitney-Pickett、Kwansik Yoon

  DOI：10.1016/j.bmcl.2011.04.077

  日期：2011.6

  High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X(7) receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein binding and a predicted short half-life in humans. Multi-parameter optimization was used to address the potency, physicochemical and pharmacokinetic properties which led to potent P2X(7)R antagonists with good disposition properties. Compound 33 (CE-224,535) was advanced to clinical studies for the treatment of rheumatoid arthritis. (C) 2011 Elsevier Ltd. All rights reserved.